Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Susoctocog Alfa · Obizur, OBIZUR

Recombinant protein · Protein replacement · developed by Takeda Pharmaceuticals U.S.A.

Approved FDA, Oct 2014
TAK Developer
1 Registered trials

What is Susoctocog Alfa?

Susoctocog alfa (Obizur) is a recombinant antihemophilic factor (Factor VIII) of porcine sequence. It replaces deficient Factor VIII to restore coagulation function in acquired hemophilia A.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Obizur, OBIZUR, BAX-802
Drug type
Recombinant protein
Mechanism
Protein replacement
Pathways
coagulation cascade
Therapy area
Hematology
Developer
Takeda Pharmaceuticals U.S.A., Inc. (TAK)
FDA status
Approved as Obizur (October 23, 2014), BLA125512
UNII
6892UQT2GK

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06550882 N/A Acquired Hemophilia A Recruiting TAK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acquired Hemophilia A

More from Takeda Pharmaceuticals U.S.A.

Maribavir FDA approved Vedolizumab FDA approved Vonicog Alfa FDA approved Elritercept Phase 3 GDX012 Phase 1/2 IGI Phase 3 Mezagitamab Phase 3 MNI-792 Phase 1 Pevonedistat Phase 2/3 Soticlestat Phase 3 TAK-186 Phase 1/2 TAK-188 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the TAK page.

Follow TAK, the company behind Susoctocog Alfa

See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TAK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.